David F. Hale
David Hale is Chairman and CEO of Hale BioPharma Ventures, LLC a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies. He serves as Chairman of three public companies Biocept, Inc., a cancer diagnostic company, Conatus Pharmaceuticals, Inc., a liver disease company and Cassiopea, Inc, a dermatology company. He served as Chairman of Santarus, Inc., prior to its sale to Salix Pharmaceuticals, Inc. in 2014, SkinMedica, Inc. prior to its sale to Allergan in 2012, Micromet, Inc. prior to its sale to Amgen Inc. in 2012, Somaxon Pharmaceuticals prior to its sale to Pernix in 2013, and Crisi Medical Systems prior to its sale to Becton-Dickinson in 2015.
In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. In 1997, he was a co-founder and served as Chairman of LMA North America until its merger with LMA International in 2004. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000, prior to joining CancerVax in October 2000, where he served as President and CEO from 2000 until its merger with Micromet, Inc, in 2006, when he became Chairman.
Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.
He is a co-founder and Chairman of Neurelis, Inc., Agility Clinical, Inc., MDRejuvena, Inc., Skylit, Inc., Recros Medica, Inc., Neurana Pharmaceuticals, Inc., Adigica Health, Inc., and a co-founder and Managing Member of Dermata Therapeutics, LLC. He is also Chairman of Colorescience, Inc., co-founder and Director of Oncternal Therapeutics, Inc. and a co-founder of Cadence, Evoke, Elevation and Zogenix.
Mr. Hale also is a co-founder and serves on the Board of Directors of BIOCOM and CONNECT and is a former member of the Board of the Biotechnology Industry Organization (BIO), and the Biotechnology Institute. He served as Chairman of the Board of Trustees of Rady Children’s Hospital and is now Chairman of the Board of the Rady Institute of Pediatric Genomics at Rady Children’s, serves on The Salk Institute Board of Trustees, is a member of the Rady School of Management Dean’s Advisory Council, and a Director of the San Diego Economic Development Corporation.
chair & CEO, Hale BioPharma Ventures; former chair, Santarus, SkinMedica & others